China Biologic Products, Inc. Form 3 May 09, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB APPROVAL FORM 3 Washington, D.C. 20549 OMB 3235-0104 Number: January 31, **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF** Expires: 2005 **SECURITIES** Estimated average burden hours per

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Ad Person <u>*</u> Feng Dai	dress of Repo	orting	2. Date of Event Requiring Statement (Month/Day/Year) 05/04/2014		3. Issuer Name and Ticker or Trading Symbol China Biologic Products, Inc. [CBPO]				
(Last)	(First)	(Middle)			4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_Director10% Owner OfficerOther			5. If Amendment, Date Original Filed(Month/Day/Year)	
C/O CBPO,Â TOWER, CH RD.								 6. Individual or Joint/Group 	
BEIJING, F4 100125					(give title below) (specify below)		Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person	
(City)	(State)	(Zip)		Table I - N	lon-Derivat	ive Securiti	es Bei	neficially Owned	
1.Title of Securi (Instr. 4)	ty			2. Amount of Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owne (Instr.	*	
Common Sto	ck, \$0.000	l par value	e per share	10,989,200)	Ι	See f	$\frac{(1)}{(2)} \frac{(2)}{(3)} \frac{(4)}{(4)}$	
Reminder: Report owned directly o		te line for ea	ch class of secu	irities benefici	ially SI	EC 1473 (7-02))		
	informa require	ation conta d to respo	oond to the c lined in this f nd unless the /IB control nu	orm are not e form displ					

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)
		(Instr. 4)	Price of	Derivative	
			Derivative	Security:	

response...

0.5

Edgar Filing: China Biologic Products, Inc. - Form 3

Date	Expiration	Title	Amount or	Security	Direct (D)
Exercisable	Date		Number of		or Indirect
			Shares		(I)
					(Instr. 5)

Reporting Owners

Reporting Owner Name / Address	Relationships				
FB	Director	10% Owner	Officer	Other	
ai PO NG INT'L TOWER, CHAO YANG PARK RD. G, F4 100125	ÂX	Â	Â	Â	
atures					

/s/ Feng Dai

**Signature of

Reporting Person

Feng Da C/O CBI JIALON BEIJINO

Signa

05/09/2014 Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This Form 3 is being filed in connection with the appointment of Mr. Dai Feng (the "Reporting Person" or "Mr. Feng") as a Director of China Biologic Products, Inc. (the "Issuer") on May 4, 2014.

The 10,989,200 shares of common stock, \$0.0001 par value per share ("Common Stock") of the Issuer are held by WP X Biologics LLC, a Delaware limited liability company ("WP X B"), Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP

(2) X") and holder of 96.9% of the equity interest in WP X B, and Warburg Pincus X Partners, L.P., a Delaware limited partnership and holder of 3.1% of the equity interest in WP X B ("WPP X", and together with WP X, the "WP X Funds"). Warburg Pincus X, L.P., a Delaware limited partnership ("WP X LP"), is the general partner of the WP X Funds. (continued on footnote 3)

Warburg Pincus X LLC, a Delaware limited liability company ("WP X LLC"), is the general partner of WP X LP. Warburg Pincus Partners LLC, a New York limited liability company ("WP Partners"), is the sole member of WP X LLC. Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WP Partners. Warburg Pincus LLC, a New York limited liability company ("WP X Funds.

Mr. Feng is a Managing Director of WP LLC. As such, Mr. Feng may be deemed to have an indirect pecuniary interest (within the meaning of Rule 16a-1 under the Securities and Exchange Act of 1934, as amended (the "Exchange Act")) in an indeterminate portion

(4) In the index of the securities and Exchange Act of 1955, as another (the Exchange Act)) in an indecommand portion of the securities reported as beneficially owned by the WP X Funds. Mr. Feng disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Mr. Feng does not directly own any shares of Common Stock of the Issuer.

Â

(3)

Remarks:

This Form 3 shall not be deemed an admission that the Reporting Person or any other person re

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.